poisar

Stocks · News reference

TScan Therapeutics Reports Third Quarter 2026 Financial Results and Strategic Reorganization

Fiscal.ai

TScan Therapeutics announced a strategic reorganization to prioritize its in vivo-engineered TCR-T cell therapy program for solid tumors while pausing enrollment in its Phase 3 ALLOHA-2 study.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGARSEC EDGAR

    8-K filing — TScan Therapeutics, Inc. (TCRX)

    Filed: 2026-11-12 AccNo: 0001193125-26-456865 Size: 411 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits